Jonathan A Javitch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1146698/publications.pdf

Version: 2024-02-01

266 papers

26,351 citations

90 h-index 152 g-index

307 all docs

307 docs citations

307 times ranked

19631 citing authors

#	Article	IF	CITATIONS
1	The Role of the Dopamine Transporter in the Effects of Amphetamine on Sleep and Sleep Architecture in Drosophila. Neurochemical Research, 2022, 47, 177-189.	1.6	6
2	Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin, 2022, 48, 199-210.	2.3	11
3	How changes in dopamine D2 receptor levels alter striatal circuit function and motivation. Molecular Psychiatry, 2022, 27, 436-444.	4.1	21
4	Mu opioid receptors on hippocampal GABAergic interneurons are critical for the antidepressant effects of tianeptine. Neuropsychopharmacology, 2022, 47, 1387-1397.	2.8	12
5	Dopamine D2 receptors modulate the cholinergic pause and inhibitory learning. Molecular Psychiatry, 2022, 27, 1502-1514.	4.1	18
6	Delineating the interactions between the cannabinoid CB ₂ receptor and its regulatory effectors; βâ€arrestins and GPCR kinases. British Journal of Pharmacology, 2022, 179, 2223-2239.	2.7	8
7	Functional Genomic Analysis of Amphetamine Sensitivity in Drosophila. Frontiers in Psychiatry, 2022, 13, 831597.	1.3	1
8	The respiratory depressant effects of mitragynine are limited by its conversion to 7â€OH mitragynine. British Journal of Pharmacology, 2022, 179, 3875-3885.	2.7	10
9	OZITX, a pertussis toxin-like protein for occluding inhibitory G protein signalling including Gαz. Communications Biology, 2022, 5, 256.	2.0	7
10	GPCR-mediated \hat{I}^2 -arrestin activation deconvoluted with single-molecule precision. Cell, 2022, 185, 1661-1675.e16.	13.5	43
11	Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science, 2022, , .	1.0	O
12	Dopamine D2 receptor overexpression in the nucleus accumbens core induces robust weight loss during scheduled fasting selectively in female mice. Molecular Psychiatry, 2021, 26, 3765-3777.	4.1	35
13	Crystal structures of LeuT reveal conformational dynamics in the outward-facing states. Journal of Biological Chemistry, 2021, 296, 100609.	1.6	10
14	Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site. ELife, 2021, 10 , .	2.8	40
15	Single-molecule FRET imaging of GPCR dimers in living cells. Nature Methods, 2021, 18, 397-405.	9.0	104
16	Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu ₂ /mGlu ₄ receptor heterodimers. Science Signaling, 2021, 14, .	1.6	14
17	New phosphosite-specific antibodies to unravel the role of GRK phosphorylation in dopamine D2 receptor regulation and signaling. Scientific Reports, 2021, 11, 8288.	1.6	19
18	Site selective Câ€"H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy. Nature Communications, 2021, 12, 3858.	5.8	25

#	Article	IF	CITATIONS
19	A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects. Journal of Medicinal Chemistry, 2021, 64, 13873-13892.	2.9	33
20	Encephalopathy-causing mutations in $\hat{Gl^21}$ (GNB1) alter regulation of neuronal GIRK channels. IScience, 2021, 24, 103018.	1.9	4
21	Cortical overgrowth in a preclinical forebrain organoid model of CNTNAP2-associated autism spectrum disorder. Nature Communications, 2021, 12, 4087.	5.8	51
22	A novel luminescence-based \hat{i}^2 -arrestin recruitment assay for unmodified receptors. Journal of Biological Chemistry, 2021, 296, 100503.	1.6	12
23	Disrupting D1-NMDA or D2-NMDA receptor heteromerization prevents cocaine's rewarding effects but preserves natural reward processing. Science Advances, 2021, 7, eabg5970.	4.7	16
24	Assays for detecting arrestin interaction with GPCRs. Methods in Cell Biology, 2021, 166, 43-65.	0.5	3
25	A nonâ€helical region in transmembrane helix 6 of hydrophobic amino acid transporter MhsT mediates substrate recognition. EMBO Journal, 2021, 40, e105164.	3.5	18
26	Tianeptine, but not fluoxetine, decreases avoidant behavior in a mouse model of early developmental exposure to fluoxetine. Scientific Reports, 2021, 11, 22852.	1.6	2
27	New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Molecular Psychiatry, 2020, 25, 2070-2085.	4.1	55
28	Come Fly with Me: An overview of dopamine receptors in <i>Drosophila melanogaster</i> . Basic and Clinical Pharmacology and Toxicology, 2020, 126, 56-65.	1.2	38
29	Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation. Molecular Psychiatry, 2020, 25, 2086-2100.	4.1	55
30	Detecting G protein-coupled receptor complexes in postmortem human brain with proximity ligation assay and a Bayesian classifier. BioTechniques, 2020, 68, 122-129.	0.8	9
31	Measuring the effects of ketamine on mGluR5 using [¹⁸ F]FPEB and PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 2254-2264.	2.4	13
32	G12/13 is activated by acute tethered agonist exposure in the adhesion GPCR ADGRL3. Nature Chemical Biology, 2020, 16, 1343-1350.	3.9	41
33	Novel Fluorescent Ligands Enable Single-Molecule Localization Microscopy of the Dopamine Transporter. ACS Chemical Neuroscience, 2020, 11, 3288-3300.	1.7	12
34	Tuning the Baird aromatic triplet-state energy of cyclooctatetraene to maximize the self-healing mechanism in organic fluorophores. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24305-24315.	3.3	35
35	Agonist-induced formation of unproductive receptor-G ₁₂ complexes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21723-21730.	3.3	35
36	Structure of human GABAB receptor in an inactive state. Nature, 2020, 584, 304-309.	13.7	59

#	Article	lF	Citations
37	Small Flies Meet Big Data: Genetic Convergence of Neurodevelopmental Disorders Modeled in <i>Drosophila</i> . American Journal of Psychiatry, 2020, 177, 482-484.	4.0	6
38	X-ray structure of LeuT in an inward-facing occluded conformation reveals mechanism of substrate release. Nature Communications, 2020, 11, 1005.	5.8	34
39	Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology, 2020, 175, 113871.	2.0	35
40	Detection of G Proteinâ€Coupled Receptor Complexes in Postmortem Human Brain by Proximity Ligation Assay. Current Protocols in Neuroscience, 2020, 91, e86.	2.6	5
41	Ribosome-associated vesicles: A dynamic subcompartment of the endoplasmic reticulum in secretory cells. Science Advances, 2020, 6, eaay9572.	4.7	42
42	Synthesis and pharmacological evaluation of bivalent tethered ligands to target the mGlu2/4 heterodimeric receptor results in a compound with mGlu2/2 homodimer selectivity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127212.	1.0	3
43	Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism. ELife, 2020, 9, .	2.8	31
44	Molecular Determinants of the Intrinsic Efficacy of the Antipsychotic Aripiprazole. ACS Chemical Biology, 2019, 14, 1780-1792.	1.6	19
45	Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA. ACS Chemical Neuroscience, 2019, 10, 4350-4360.	1.7	39
46	The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface. Journal of Biological Chemistry, 2019, 294, 5604-5615.	1.6	18
47	Genetically Targeted Optical Control of an Endogenous G Protein-Coupled Receptor. Journal of the American Chemical Society, 2019, 141, 11522-11530.	6.6	51
48	7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Central Science, 2019, 5, 992-1001.	5.3	120
49	Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence. Frontiers in Pharmacology, 2019, 10, 350.	1.6	58
50	Quantifying secondary transport at single-molecule resolution. Nature, 2019, 575, 528-534.	13.7	37
51	The allosteric mechanism of substrate-specific transport in SLC6 is mediated by a volumetric sensor. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15947-15956.	3.3	23
52	Role of Tau Protein in Remodeling of Circadian Neuronal Circuits and Sleep. Frontiers in Aging Neuroscience, 2019, 11, 320.	1.7	26
53	Regional Heterogeneity of D2-Receptor Signaling in the Dorsal Striatum and Nucleus Accumbens. Neuron, 2018, 98, 575-587.e4.	3.8	52
54	Gs-Âversus Golf-dependent functional selectivity mediated by the dopamine D1 receptor. Nature Communications, 2018, 9, 486.	5 . 8	38

#	Article	IF	Citations
55	A partially-open inward-facing intermediate conformation of LeuT is associated with Na+ release and substrate transport. Nature Communications, 2018, 9, 230.	5.8	40
56	Phosphorylation of the Amino Terminus of the Dopamine Transporter: Regulatory Mechanisms and Implications for Amphetamine Action. Advances in Pharmacology, 2018, 82, 205-234.	1.2	13
57	The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions. Scientific Reports, 2018, 8, 1208.	1.6	16
58	The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D 2 receptor. Biochemical Pharmacology, 2018, 148, 315-328.	2.0	26
59	Accumbens dopamine D2 receptors increase motivation by decreasing inhibitory transmission to the ventral pallidum. Nature Communications, 2018, 9, 1086.	5.8	92
60	Treatment resistant depression: A multi-scale, systems biology approach. Neuroscience and Biobehavioral Reviews, 2018, 84, 272-288.	2.9	319
61	Reply to †Antipsychotics with similar association kinetics at dopamine D2 receptors differ in extrapyramidal side-effects'. Nature Communications, 2018, 9, 3568.	5.8	2
62	Exploring Substrate Binding in the Extracellular Vestibule of MhsT by Atomistic Simulations and Markov Models. Journal of Chemical Information and Modeling, 2018, 58, 1244-1252.	2.5	4
63	Luciferase complementation based-detection of G-protein-coupled receptor activity. BioTechniques, 2018, 65, 9-14.	0.8	12
64	The LeuT-fold neurotransmitter:sodium symporter MhsT has two substrate sites. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7924-E7931.	3.3	21
65	The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. PLoS Computational Biology, 2018, 14, e1005948.	1.5	19
66	Potentiating SLC transporter activity: Emerging drug discovery opportunities. Biochemical Pharmacology, 2017, 135, 1-11.	2.0	47
67	Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 449-456.	1.1	47
68	Phospho-specific antibodies targeting the amino terminus of the human dopamine transporter. Journal of Chemical Neuroanatomy, 2017, 83-84, 91-98.	1.0	7
69	Single-molecule analysis of ligand efficacy in β2AR–G-protein activation. Nature, 2017, 547, 68-73.	13.7	265
70	The role of transmembrane segment 5 (TM5) in Na2 release and the conformational transition of neurotransmitter:sodium symporters toward the inward-open state. Journal of Biological Chemistry, 2017, 292, 7372-7384.	1.6	21
71	The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor. Neuropsychopharmacology, 2017, 42, 2052-2063.	2.8	240
72	Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D ₃ Receptor. Journal of Medicinal Chemistry, 2017, 60, 580-593.	2.9	49

#	Article	IF	Citations
73	Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nature Communications, 2017, 8, 763.	5.8	148
74	Development of novel biosensors to study receptor-mediated activation of the G-protein \hat{l}_{\pm} subunits Gs and Golf. Journal of Biological Chemistry, 2017, 292, 19989-19998.	1.6	14
75	Extreme Vetting of Dopamine Receptor Oligomerization. , 2017, , 99-127.		3
76	Neuronal Depolarization Drives Increased Dopamine Synaptic Vesicle Loading via VGLUT. Neuron, 2017, 95, 1074-1088.e7.	3.8	69
77	Optical Control of Dopamine Receptors Using a Photoswitchable Tethered Inverse Agonist. Journal of the American Chemical Society, 2017, 139, 18522-18535.	6.6	63
78	InÂvivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [¹¹ C]ABP688 and [¹⁸ F]FPEB. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2716-2727.	2.4	49
79	Electronic tuning of self-healing fluorophores for live-cell and single-molecule imaging. Chemical Science, 2017, 8, 755-762.	3.7	58
80	Dopamine D2 Receptors in the Paraventricular Thalamus Attenuate Cocaine Locomotor Sensitization. ENeuro, 2017, 4, ENEURO.0227-17.2017.	0.9	37
81	Novel Analogues of (<i>R</i>)-5-(Methylamino)-5,6-dihydro-4 <i>H</i> -imidazo[4,5,1- <i>ij</i>]quinolin-2(1 <i>H</i>)-one (Sumanirole) Provide Clues to Dopamine D ₂ /D ₃ Receptor Agonist Selectivity. lournal of Medicinal Chemistry, 2016, 59, 2973-2988.	2.9	33
82	Synthetic and Receptor Signaling Explorations of the <i>Mitragyna</i> Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. Journal of the American Chemical Society, 2016, 138, 6754-6764.	6.6	233
83	Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nature Communications, 2016, 7, 10652.	5.8	97
84	Conformational Dynamics on the Extracellular Side of LeuT Controlled by Na+ and K+ Ions and the Protonation State of Glu290. Journal of Biological Chemistry, 2016, 291, 19786-19799.	1.6	22
85	Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu _{2/4} Heteromers. ACS Chemical Neuroscience, 2016, 7, 1201-1211.	1.7	50
86	The role of kinetic context in apparent biased agonism at GPCRs. Nature Communications, 2016, 7, 10842.	5.8	270
87	Role of Annular Lipids in the Functional Properties of Leucine Transporter LeuT Proteomicelles. Biochemistry, 2016, 55, 850-859.	1.2	12
88	Development of a Rapid Insulin Assay by Homogenous Time-Resolved Fluorescence. PLoS ONE, 2016, 11, e0148684.	1.1	27
89	Using Bioluminescence Resonance Energy Transfer (BRET) to Characterize Agonistâ€Induced Arrestin Recruitment to Modified and Unmodified G Proteinâ€Coupled Receptors. Current Protocols in Pharmacology, 2015, 70, 2.14.1-2.14.14.	4.0	41
90	Evidence against dopamine D1/D2 receptor heteromers. Molecular Psychiatry, 2015, 20, 1373-1385.	4.1	100

#	Article	IF	Citations
91	Dual agonist occupancy of AT1-R–α2C-AR heterodimers results in atypical Gs-PKA signaling. Nature Chemical Biology, 2015, 11, 271-279.	3.9	83
92	Evidence for limited D1 and D2 receptor coexpression and colocalization within the dorsal striatum of the neonatal mouse. Journal of Comparative Neurology, 2015, 523, 1175-1189.	0.9	27
93	High Affinity Dopamine D ₃ Receptor (D ₃ R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D ₃ R Knockout Mice. Journal of Medicinal Chemistry, 2015, 58, 6195-6213.	2.9	45
94	Upregulation of Dopamine D2 Receptors in the Nucleus Accumbens Indirect Pathway Increases Locomotion but Does Not Reduce Alcohol Consumption. Neuropsychopharmacology, 2015, 40, 1609-1618.	2.8	38
95	Substrate-induced Unlocking of the Inner Gate Determines the Catalytic Efficiency of a Neurotransmitter:Sodium Symporter. Journal of Biological Chemistry, 2015, 290, 26725-26738.	1.6	32
96	Mechanism of the Association between Na+ Binding and Conformations at the Intracellular Gate in Neurotransmitter:Sodium Symporters. Journal of Biological Chemistry, 2015, 290, 13992-14003.	1.6	58
97	What Can Crystal Structures of Aminergic Receptors Tell Us about Designing Subtype-Selective Ligands?. Pharmacological Reviews, 2015, 67, 198-213.	7.1	99
98	Imaging Functional Dynamic Processes within Integral Membrane Proteins at the Singleâ€Molecule Scale. FASEB Journal, 2015, 29, 498.3.	0.2	0
99	Mutation of Three Residues in the Third Intracellular Loop of the Dopamine D2 Receptor Creates an Internalization-defective Receptor. Journal of Biological Chemistry, 2014, 289, 33663-33675.	1.6	32
100	Conformational dynamics of ligand-dependent alternating access in LeuT. Nature Structural and Molecular Biology, 2014, 21, 472-479.	3.6	136
101	Cross-Talk between G Protein-Coupled Receptors. , 2014, , 93-94.		0
102	Rebuttal from Nevin A. Lambert and Jonathan A. Javitch. Journal of Physiology, 2014, 592, 2449-2449.	1.3	12
103	Conformational changes in dopamine transporter intracellular regions upon cocaine binding and dopamine translocation. Neurochemistry International, 2014, 73, 4-15.	1.9	13
104	A mechanism for intracellular release of Na+ by neurotransmitter/sodium symporters. Nature Structural and Molecular Biology, 2014, 21, 1006-1012.	3.6	159
105	Identification of Novel Functionally Selective $\langle i \rangle \hat{l}^e \langle i \rangle$ -Opioid Receptor Scaffolds. Molecular Pharmacology, 2014, 85, 83-90.	1.0	117
106	CrossTalk opposing view: Weighing the evidence for classÂA GPCR dimers, the jury is still out. Journal of Physiology, 2014, 592, 2443-2445.	1.3	74
107	A new mechanism of allostery in a G protein–coupled receptor dimer. Nature Chemical Biology, 2014, 10, 745-752.	3.9	108
108	The atypical antidepressant and neurorestorative agent tianeptine is a \hat{l} 4-opioid receptor agonist. Translational Psychiatry, 2014, 4, e411-e411.	2.4	107

#	Article	IF	Citations
109	Discovery and Characterization of a G Protein–Biased Agonist That Inhibits <i>β</i>) Arrestin Recruitment to the D2 Dopamine Receptor. Molecular Pharmacology, 2014, 86, 96-105.	1.0	74
110	PIP2 regulates psychostimulant behaviors through its interaction with a membrane protein. Nature Chemical Biology, 2014, 10, 582-589.	3.9	109
111	Dopamine Receptor Activation Increases HIV Entry into Primary Human Macrophages. PLoS ONE, 2014, 9, e108232.	1.1	63
112	Towards Better Understanding of G(s) Coupling in Catecholamine Receptors. , 2014, , 89-90.		0
113	The Membrane-Raft Protein Flotillin-1 is Essential in Dopamine Neurons for Amphetamine-Induced Behavior in Drosophila. , 2014, , 58.		0
114	Drug Design for Addiction – Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor. , 2014, , 181-182.		0
115	Deciphering the Functionally Selective Properties of D2R Ligands. , 2014, , 110.		0
116	High-Throughput Screening for Modulators of the D2 Dopamine Receptor Yields Unique and Selective Pharmacological Chemotypes. , 2014, , 115.		0
117	The Membrane Protein LeuT in Micellar Systems: Aggregation Dynamics and Detergent Binding to the S2 Site. Journal of the American Chemical Society, 2013, 135, 14266-14275.	6.6	32
118	Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening. Journal of Chemical Information and Modeling, 2013, 53, 521-526.	2.5	58
119	Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation. Molecular Psychiatry, 2013, 18, 1025-1033.	4.1	162
120	Segregation of Family A G Protein–Coupled Receptor Protomers in the Plasma Membrane. Molecular Pharmacology, 2013, 84, 346-352.	1.0	26
121	Chloride binding site of neurotransmitter sodium symporters. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8489-8494.	3 . 3	85
122	A Single Glycine in Extracellular Loop 1 Is the Critical Determinant for Pharmacological Specificity of Dopamine D2 and D3 Receptors. Molecular Pharmacology, 2013, 84, 854-864.	1.0	58
123	Sensing conformational changes in metabotropic glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5742-5743.	3.3	1
124	Getting to grips with ammonium. ELife, 2013, 2, e01029.	2.8	1
125	6′-Guanidinonaltrindole (6′-GNTI) Is a G Protein-biased κ-Opioid Receptor Agonist That Inhibits Arrestin Recruitment. Journal of Biological Chemistry, 2012, 287, 27050-27054.	1.6	96
126	Dopamine-Mediated Autocrine Inhibitory Circuit Regulating Human Insulin Secretion in Vitro. Molecular Endocrinology, 2012, 26, 1757-1772.	3.7	74

#	Article	IF	Citations
127	Experimental conditions can obscure the second high-affinity site in LeuT. Nature Structural and Molecular Biology, 2012, 19, 207-211.	3.6	84
128	Cyanine fluorophore derivatives with enhanced photostability. Nature Methods, 2012, 9, 68-71.	9.0	269
129	Yohimbine Depresses Excitatory Transmission in BNST and Impairs Extinction of Cocaine Place Preference Through Orexin-Dependent, Norepinephrine-Independent Processes. Neuropsychopharmacology, 2012, 37, 2253-2266.	2.8	29
130	Structure and functional interaction of the extracellular domain of human GABAB receptor GBR2. Nature Neuroscience, 2012, 15, 970-978.	7.1	61
131	Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor. Journal of Medicinal Chemistry, 2012, 55, 6689-6699.	2.9	153
132	Imaging the high-affinity state of the dopamine D2 receptor in vivo: Fact or fiction?. Biochemical Pharmacology, 2012, 83, 193-198.	2.0	59
133	CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nature Chemical Biology, 2011, 7, 624-630.	3.9	107
134	Making Structural Sense of Dimerization Interfaces of Delta Opioid Receptor Homodimers. Biochemistry, 2011, 50, 1682-1690.	1.2	70
135	Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. BioTechniques, 2011, 51, 111-118.	0.8	230
136	Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. Nature Neuroscience, 2011, 14, 469-477.	7.1	177
137	Characterization of in vivo Pharmacokinetic Properties of the Dopamine D1 Receptor Agonist DAR-0100A in Nonhuman Primates Using PET with [11C] NNC112 and [11C] Raclopride. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 293-304.	2.4	21
138	Crystal structure of a potassium ion transporter, TrkH. Nature, 2011, 471, 336-340.	13.7	120
139	Crystal structure of a phosphorylation-coupled saccharide transporter. Nature, 2011, 473, 50-54.	13.7	77
140	Substrate-modulated gating dynamics in a Na+-coupled neurotransmitter transporter homologue. Nature, 2011, 474, 109-113.	13.7	276
141	Chapter 12. Crosstalk Between Receptors: Challenges of Distinguishing Upstream from Downstream Mechanisms. RSC Drug Discovery Series, 2011, , 255-268.	0.2	0
142	Discovery of β-Arrestin–Biased Dopamine D ₂ Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18488-18493.	3.3	312
143	Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20766-20771.	3.3	161
144	Presynaptic Regulation of Dopamine Transmission in Schizophrenia. Schizophrenia Bulletin, 2011, 37, 108-117.	2.3	56

#	Article	IF	Citations
145	The Substrate-Driven Transition to an Inward-Facing Conformation in the Functional Mechanism of the Dopamine Transporter. PLoS ONE, 2011, 6, e16350.	1.1	107
146	Ion/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter:sodium symporters. Nature Structural and Molecular Biology, 2010, 17, 822-829.	3.6	183
147	Single-molecule dynamics of gating in a neurotransmitter transporter homologue. Nature, 2010, 465, 188-193.	13.7	239
148	Substrate-dependent proton antiport in neurotransmitter:sodium symporters. Nature Chemical Biology, 2010, 6, 109-116.	3.9	59
149	Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nature Chemical Biology, 2010, 6, 587-594.	3.9	306
150	Dysregulation of Dopamine Transporters via Dopamine D ₂ Autoreceptors Triggers Anomalous Dopamine Efflux Associated with Attention-Deficit Hyperactivity Disorder. Journal of Neuroscience, 2010, 30, 6048-6057.	1.7	105
151	Exploring the Binding Site Crevice of a Family B G Protein-Coupled Receptor, the Type 1 Corticotropin Releasing Factor Receptor. Molecular Pharmacology, 2010, 78, 785-793.	1.0	10
152	GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics, 2010, 26, 1804-1805.	1.8	74
153	The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D ₃ and D ₂ Receptors. Molecular Pharmacology, 2010, 78, 925-934.	1.0	57
154	Roles of the Akt/GSK-3 and Wnt Signaling Pathways in Schizophrenia and Antipsychotic Drug Action. American Journal of Psychiatry, 2010, 167, 388-396.	4.0	254
155	Akt-Dependent and Isoform-Specific Regulation of Dopamine Transporter Cell Surface Expression. ACS Chemical Neuroscience, 2010, 1, 476-481.	1.7	28
156	Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist. Science, 2010, 330, 1091-1095.	6.0	1,034
157	Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends in Pharmacological Sciences, 2010, 31, 381-390.	4.0	159
158	Structureâ [^] Activity Relationships for a Novel Series of Citalopram (1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) Analogues at Monoamine Transporters. Journal of Medicinal Chemistry, 2010, 53, 6112-6121.	2.9	39
159	Impact of D2 Receptor Internalization on Binding Affinity of Neuroimaging Radiotracers. Neuropsychopharmacology, 2010, 35, 806-817.	2.8	71
160	TRAC: A Platform for Structure-Function Studies of NSS-Proteins Integrates Information from Bioinformatics and Biomedical Literature. , 2010, , .		1
161	Structural Basis of Dopamine Receptor Activation. , 2010, , 47-73.		4
162	Lipid rafts and membrane cholesterol are involved in regulating D2 dopamine receptor signaling. FASEB Journal, 2010, 24, 584.1.	0.2	0

#	Article	IF	Citations
163	Amphetamine and Methamphetamine Differentially Affect Dopamine Transporters in Vitro and in Vivo. Journal of Biological Chemistry, 2009, 284, 2978-2989.	1.6	168
164	Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the Protean Effects of "Selective―Antagonists. Journal of Biological Chemistry, 2009, 284, 31270-31279.	1.6	146
165	Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5563-5568.	3.3	184
166	G Protein-coupled Receptor Kinase-2 Constitutively Regulates D2 Dopamine Receptor Expression and Signaling Independently of Receptor Phosphorylation. Journal of Biological Chemistry, 2009, 284, 34103-34115.	1.6	67
167	G Protein-coupled Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D2 Dopamine Receptor. Journal of Biological Chemistry, 2009, 284, 15038-15051.	1.6	83
168	A Juxtamembrane Mutation in the N Terminus of the Dopamine Transporter Induces Preference for an Inward-Facing Conformation. Molecular Pharmacology, 2009, 75, 514-524.	1.0	61
169	Two allelic isoforms of the serotonin transporter from Schistosoma mansoni display electrogenic transport and high selectivity for serotonin. European Journal of Pharmacology, 2009, 616, 48-57.	1.7	23
170	Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nature Chemical Biology, 2009, 5, 688-695.	3.9	323
171	Building a new conceptual framework for receptor heteromers. Nature Chemical Biology, 2009, 5, 131-134.	3.9	349
172	Human Immunodeficiency Virus (HIV) Infection of Human Macrophages Is Increased by Dopamine. American Journal of Pathology, 2009, 175, 1148-1159.	1.9	115
173	The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8043-8048.	3.3	183
174	Drs. Lieberman, Javitch, and Moore Reply. American Journal of Psychiatry, 2009, 166, 111-113.	4.0	4
175	Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO Journal, 2008, 27, 2293-2304.	3.5	305
176	Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Molecular Psychiatry, 2008, 13, 918-929.	4.1	95
177	The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nature Neuroscience, 2008, 11, 780-789.	7.1	304
178	Syntaxin 1A Interaction with the Dopamine Transporter Promotes Amphetamine-Induced Dopamine Efflux. Molecular Pharmacology, 2008, 74, 1101-1108.	1.0	114
179	The Mechanism of a Neurotransmitter:Sodium Symporter—Inward Release of Na+ and Substrate IsÂTriggered by Substrate in a Second Binding Site. Molecular Cell, 2008, 30, 667-677.	4.5	352
180	Recruitment of \hat{l}^2 -arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology, 2008, 54, 1215-1222.	2.0	70

#	Article	IF	CITATIONS
181	PI3K signaling supports amphetamine-induced dopamine efflux. Biochemical and Biophysical Research Communications, 2008, 372, 656-661.	1.0	36
182	Currents in Response to Rapid Concentration Jumps of Amphetamine Uncover Novel Aspects of Human Dopamine Transporter Function. Journal of Neuroscience, 2008, 28, 976-989.	1.7	61
183	An Intracellular Interaction Network Regulates Conformational Transitions in the Dopamine Transporter. Journal of Biological Chemistry, 2008, 283, 17691-17701.	1.6	120
184	Cholinergic Agonists as Novel Treatments for Schizophrenia: The Promise of Rational Drug Development for Psychiatry. American Journal of Psychiatry, 2008, 165, 931-936.	4.0	49
185	Regulation of Dopamine Transporter Function and Cell Surface Expression by D3 Dopamine Receptors. Journal of Biological Chemistry, 2007, 282, 35842-35854.	1.6	101
186	International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers. Pharmacological Reviews, 2007, 59, 5-13.	7.1	274
187	D2 Receptors Regulate Dopamine Transporter Function via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent and Phosphoinositide 3 Kinase-Independent Mechanism. Molecular Pharmacology, 2007, 71, 1222-1232.	1.0	182
188	Monitoring the function of membrane transport proteins in detergent-solubilized form. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3603-3608.	3.3	172
189	Functional Selectivity and Classical Concepts of Quantitative Pharmacology. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 1-13.	1.3	997
190	Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature, 2007, 449, 726-730.	13.7	212
191	Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics, 2007, 8, 177.	1.2	42
192	Calmodulin Kinase II Interacts with the Dopamine Transporter C Terminus to Regulate Amphetamine-Induced Reverse Transport. Neuron, 2006, 51, 417-429.	3.8	197
193	A Role for Information Collection, Management, and Integration in Structure-Function Studies of G-Protein Coupled Receptors. Current Pharmaceutical Design, 2006, 12, 1771-1783.	0.9	8
194	State-dependent Conformations of the Translocation Pathway in the Tyrosine Transporter Tyt1, a Novel Neurotransmitter:Sodium Symporter from Fusobacterium nucleatum. Journal of Biological Chemistry, 2006, 281, 26444-26454.	1.6	88
195	A Comprehensive Structure-Based Alignment of Prokaryotic and Eukaryotic Neurotransmitter/Na+Symporters (NSS) Aids in the Use of the LeuT Structure to Probe NSS Structure and Function. Molecular Pharmacology, 2006, 70, 1630-1642.	1.0	248
196	Regulation of Dopamine Transporter Trafficking by Intracellular Amphetamine. Molecular Pharmacology, 2006, 70, 542-548.	1.0	66
197	Transmembrane five effects on functional selectivity at the dopamine D2L receptor. FASEB Journal, 2006, 20, A246.	0.2	0
198	Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding. VOLUME 279 (2004) PAGES 3228-3238. Journal of Biological Chemistry, 2006, 281, 25867-25868.	1.6	0

#	Article	IF	CITATIONS
199	How did the neurotransmitter cross the bilayer? A closer view. Current Opinion in Neurobiology, 2005, 15, 296-304.	2.0	40
200	From The Cover: Crosstalk in G protein-coupled receptors: Changes at the transmembrane homodimer interface determine activation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17495-17500.	3.3	277
201	Akt Is Essential for Insulin Modulation of Amphetamine-Induced Human Dopamine Transporter Cell-Surface Redistribution. Molecular Pharmacology, 2005, 68, 102-109.	1.0	132
202	Amphetamine induces dopamine efflux through a dopamine transporter channel. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3495-3500.	3.3	246
203	Oligomerization Domains of G Protein-Coupled Receptors. Contemporary Clinical Neuroscience, 2005, , 243-265.	0.3	4
204	Intramolecular cross-linking in a bacterial homolog of mammalian SLC6 neurotransmitter transporters suggests an evolutionary conserved role of transmembrane segments 7 and 8. Neuropharmacology, 2005, 49, 715-723.	2.0	11
205	A pincer-like configuration of TM2 in the human dopamine transporter is responsible for indirect effects on cocaine binding. Neuropharmacology, 2005, 49, 780-790.	2.0	42
206	Conformational Plasticity of GPCR Binding Sites. Contemporary Clinical Neuroscience, 2005, , 363-388.	0.3	1
207	Identification of Intracellular Residues in the Dopamine Transporter Critical for Regulation of Transporter Conformation and Cocaine Binding. Journal of Biological Chemistry, 2004, 279, 3228-3238.	1.6	85
208	Synergistic Contributions of the Functional Groups of Epinephrine to Its Affinity and Efficacy at the \hat{l}^2 2Adrenergic Receptor. Molecular Pharmacology, 2004, 65, 1181-1190.	1.0	89
209	Intracellular Ca2+Regulates Amphetamine-Induced Dopamine Efflux and Currents Mediated by the Human Dopamine Transporter. Molecular Pharmacology, 2004, 66, 137-143.	1.0	89
210	Amphetamine Regulation of Dopamine Transport. Journal of Biological Chemistry, 2004, 279, 8966-8975.	1.6	85
211	The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 440-445.	3.3	210
212	Surface Targeting of the Dopamine Transporter Involves Discrete Epitopes in the Distal C Terminus But Does Not Require Canonical PDZ Domain Interactions. Journal of Neuroscience, 2004, 24, 7024-7036.	1.7	82
213	The Ants Go Marching Two by Two: Oligomeric Structure of G-Protein-Coupled Receptors. Molecular Pharmacology, 2004, 66, 1077-1082.	1.0	92
214	Finding needles in haystacks. Nature Biotechnology, 2004, 22, 394-396.	9.4	0
215	N-Terminal Phosphorylation of the Dopamine Transporter Is Required for Amphetamine-Induced Efflux. PLoS Biology, 2004, 2, e78.	2.6	221
216	Sodium-Dependent Neurotransmitter TRANSPORTERS: OLIGOMERIZATION as a Determinant of Transporter Function and Trafficking. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2004, 4, 38-47.	3.4	119

#	Article	IF	CITATIONS
217	A Structural Context for Studying Neurotransmitter Transporter Function. , 2004, , 213-234.		1
218	Probing conformational changes in neurotransmitter transporters: a structural context. European Journal of Pharmacology, 2003, 479, 3-12.	1.7	38
219	The Fourth Transmembrane Segment Forms the Interface of the Dopamine D2 Receptor Homodimer. Journal of Biological Chemistry, 2003, 278, 4385-4388.	1.6	257
220	The Human Dopamine Transporter Forms a Tetramer in the Plasma Membrane. Journal of Biological Chemistry, 2003, 278, 45045-45048.	1.6	109
221	Characterization of a Functional Bacterial Homologue of Sodium-dependent Neurotransmitter Transporters. Journal of Biological Chemistry, 2003, 278, 12703-12709.	1.6	86
222	Dopamine Prevents Nitration of Tyrosine Hydroxylase by Peroxynitrite and Nitrogen Dioxide. Journal of Biological Chemistry, 2003, 278, 28736-28742.	1.6	25
223	N-terminal Truncation of the Dopamine Transporter Abolishes Phorbol Ester- and Substance P Receptor-stimulated Phosphorylation without Impairing Transporter Internalization. Journal of Biological Chemistry, 2003, 278, 4990-5000.	1.6	152
224	Amphetamine-induced Dopamine Efflux. Journal of Biological Chemistry, 2003, 278, 12070-12077.	1.6	174
225	Mitogen-Activated Protein Kinase Regulates Dopamine Transporter Surface Expression and Dopamine Transport Capacity. Journal of Neuroscience, 2003, 23, 8480-8488.	1.7	239
226	The Binding Pocket of G-Protein-Coupled Receptors for Biogenic Amines, Retinal, and Other Ligands. , $2003, 155-160.$		0
227	Î ² 2 Adrenergic Receptor Activation. Journal of Biological Chemistry, 2002, 277, 40989-40996.	1.6	339
228	Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors. Methods in Enzymology, 2002, 343, 137-156.	0.4	53
229	Cocaine Increases Dopamine Uptake and Cell Surface Expression of Dopamine Transporters. Biochemical and Biophysical Research Communications, 2002, 290, 1545-1550.	1.0	156
230	THEBINDINGSITE OFAMINERGICG PROTEIN–COUPLEDRECEPTORS: The Transmembrane Segments and Second Extracellular Loop. Annual Review of Pharmacology and Toxicology, 2002, 42, 437-467.	4.2	318
231	Zn2+site engineering at the oligomeric interface of the dopamine transporter. FEBS Letters, 2002, 524, 87-91.	1.3	36
232	Peroxynitrite Inactivates the Human Dopamine Transporter by Modification of Cysteine 342: Potential Mechanism of Neurotoxicity in Dopamine Neurons. Journal of Neuroscience, 2002, 22, 4399-4405.	1.7	94
233	PI 3-kinase regulation of dopamine uptake. Journal of Neurochemistry, 2002, 81, 859-869.	2.1	186
234	Comparison of the Amino Acid Residues in the Sixth Transmembrane Domains Accessible in the Binding-Site Crevices of $\hat{l}^{1}/4$, \hat{l}' , and \hat{l}^{0} Opioid Receptors. Biochemistry, 2001, 40, 8018-8029.	1.2	32

#	Article	IF	Citations
235	The First Transmembrane Segment of the Dopamine D2 Receptor:Â Accessibility in the Binding-Site Crevice and Position in the Transmembrane Bundle. Biochemistry, 2001, 40, 12339-12348.	1.2	60
236	Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. Journal of Neurochemistry, 2001, 76, 1242-1251.	2.1	175
237	Mechanisms of inverse agonism of antipsychotic drugs at the D2 dopamine receptor: use of a mutant D2 dopamine receptor that adopts the activated conformation. Journal of Neurochemistry, 2001, 77, 493-504.	2.1	56
238	[3H]MFZ 2-12: A Novel Radioligand for the Dopamine Transporter. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1659-1661.	1.0	11
239	Activation of the \hat{I}^2 2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6. Journal of Biological Chemistry, 2001, 276, 29171-29177.	1.6	566
240	Structural Mimicry in G Protein-Coupled Receptors: Implications of the High-Resolution Structure of Rhodopsin for Structure-Function Analysis of Rhodopsin-Like Receptors. Molecular Pharmacology, 2001, 60, 1-19.	1.0	432
241	Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10055-10060.	3.3	187
242	The Uptake Inhibitors Cocaine and Benztropine Differentially Alter the Conformation of the Human Dopamine Transporter. Journal of Biological Chemistry, 2001, 276, 29012-29018.	1.6	93
243	Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Molecular Pharmacology, 2001, 60, 1-19.	1.0	119
244	The Forgotten Serine. Journal of Biological Chemistry, 2000, 275, 37779-37788.	1.6	172
245	Transport-dependent Accessibility of a Cytoplasmic Loop Cysteine in the Human Dopamine Transporter. Journal of Biological Chemistry, 2000, 275, 1608-1614.	1.6	55
246	Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 6850-6855.	3.3	346
247	The Conserved Cysteine 7.38 Residue Is Differentially Accessible in the Binding-Site Crevices of the μ, δ, and κ Opioid Receptorsâ€. Biochemistry, 2000, 39, 13904-13915.	1.2	32
248	The Fourth Transmembrane Segment of the Dopamine D2 Receptor:  Accessibility in the Binding-Site Crevice and Position in the Transmembrane Bundle. Biochemistry, 2000, 39, 12190-12199.	1.2	65
249	Dopamine D4/D2 Receptor Selectivity Is Determined by A Divergent Aromatic Microdomain Contained within the Second, Third, and Seventh Membrane-Spanning Segments. Molecular Pharmacology, 1999, 56, 1116-1126.	1.0	92
250	Mutation of a Highly Conserved Aspartic Acid in the \hat{l}^2 sub>2Adrenergic Receptor: Constitutive Activation, Structural Instability, and Conformational Rearrangement of Transmembrane Segment 6. Molecular Pharmacology, 1999, 56, 175-184.	1.0	214
251	Chloroethylclonidine and 2-Aminoethyl Methanethiosulfonate Recognize Two Different Conformations of the Human $\hat{l}\pm2$ A-Adrenergic Receptor. Journal of Biological Chemistry, 1999, 274, 21867-21872.	1.6	33
252	Electrostatic and Aromatic Microdomains within the Binding-Site Crevice of the D2 Receptor:Â Contributions of the Second Membrane-Spanning Segmentâ€. Biochemistry, 1999, 38, 7961-7968.	1.2	70

#	Article	IF	CITATIONS
253	The Substitutedâ€Cysteine Accessibility Method (SCAM) to Elucidate Membrane Protein Structure. Current Protocols in Neuroscience, 1999, 8, Unit 4.15.	2.6	8
254	A Cluster of Aromatic Residues in the Sixth Membrane-Spanning Segment of the Dopamine D2 Receptor Is Accessible in the Binding-Site Crevice. Biochemistry, 1998, 37, 998-1006.	1.2	165
255	[23] Probing structure of neurotransmitter transporters by substituted-cysteine accessibility method. Methods in Enzymology, 1998, 296, 331-346.	0.4	47
256	Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9238-9243.	3.3	124
257	Constitutive Activation of the \hat{I}^2 2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment. Journal of Biological Chemistry, 1997, 272, 18546-18549.	1.6	183
258	Mapping the Binding-Site Crevice of the D2 Receptor. Advances in Pharmacology, 1997, 42, 412-415.	1.2	14
259	Residues in the Seventh Membrane-Spanning Segment of the Dopamine D2 Receptor Accessible in the Binding-Site Crevice. Biochemistry, 1996, 35, 11278-11285.	1.2	121
260	Residues in the Fifth Membrane-Spanning Segment of the Dopamine D2 Receptor Exposed in the Binding-Site Crevice. Biochemistry, 1995, 34, 16433-16439.	1.2	106
261	Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method. Neuron, 1995, 14, 825-831.	3.8	179
262	A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 10355-10359.	3.3	130
263	Differential visualization of dopamine D2 and D3 receptors in rat brain. European Journal of Pharmacology, 1993, 234, 269-272.	1.7	16
264	Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 2173-2177.	3.3	1,138
265	Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. European Journal of Pharmacology, 1984, 106, 455-456.	1.7	265
266	[3H]mazindol binding associated with neuronal dopamine uptake sites in corpus striatum membranes. European Journal of Pharmacology, 1983, 90, 461-462.	1.7	96